This brand name is authorized in Turkey.
The drug HIERO contains one active pharmaceutical ingredient (API):
1
|
UNII
2BTY8KH53L - DEFERIPRONE
|
|
Deferiprone is a bidentate ligand which binds iron in a 3:1 molar ratio. Deferiprone monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| V03AC02 | Deferiprone | V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AC Iron chelating agents |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8699738090487 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.